Discovery of how madecassic acid interacts with proteins and cellular processes:
- G. N. Sansom, E. P. Friar, D. Shorthouse, T. T. P. Tran, F. Sialana Jr, T. T. Do, C. V. Tran, Y. T. H. Be, S. V. Tran, M. D. Garrett, C. J. Serpell, Identification of molecular pathways involved in the anti-liver cancer activity of madecassic acid, BioRxiv, 2025, DOI: 10.1101/2025.08.17.670739
Survey results for medicinal use of C. asiatica in the context of liver cancer in Vietnam:
- Y. T. H. Be, K. T. Hoang, H. D. Quoc, M. D. Garrett, C. J. Serpell, R. Cassidy, Perceptions and use of traditional medicine/Centella Asiatica (Rau Ma) for cancer treatment in Vietnam: A quantitative survey study, MedRxiv, 2025, DOI: 10.1101/2025.08.17.25333874
Sustainable farming of C. asiatica for madecassic acid and other triterpenoids:
- T. T. P. Tran, N. T. Pham, N. X. Nguyen, C. V. Tran, L. V. Tran, L. T. Nguyen, D. T. Nguyen, N. T. N. Huynh, T. L. Nguyen, Y. T. H. Be, M. D. Garrett, C. J. Serpell, S. V. Tran, Comparison of organic and conventional production methods in accumulation of biomass and bioactive compounds in Centella asiatica (L.) urban, ChemRxiv, 2023, DOI: 10.26434/chemrxiv-2023-q9vvc
Madecassic acid-silybin conjugate molecules tested against liver cancer cells:
- C. V. Tran, T. T. P. Tran, A. T. Nguyen, L. V. Tran, N. T. Pham, L. T. Nguyen, D. T. Nguyen, M. D. Garrett, N. T. Nguyen, T. T. Do, C. J. Serpell, S. V. Tran, Synthesis and cytotoxic activity of madecassic acid–silybin conjugate compounds in liver cancer cells, RSC Med. Chem., 2024,15, 3418-3432
- C. V. Tran, T. T. P. Tran, A. T. Nguyen, L. V. Tran, M. D. Garrett, T. T. Do, C. J. Serpell, S. V. Tran, Regioselectively Acetylated Silybin Derivatives and their Cytotoxic Activity in Liver Cancer Cells, BioRxiv, 2025, DOI: 10.1101/2025.02.13.638106
Potential role for madecassic acid in antibacterials:
- S. A. Henry, G. Sansom, T. T. P. Tran, M. D. Garrett, G. K. Robinson, C. J. Serpell, M. Shepherd, Investigating the role of cytochrome bd oxidases in the antibacterial activity of madecassic acid and derivatives thereof, ChemRxiv, 2025, DOI: 10.26434/chemrxiv-2025-6wj5j
Anticancer properties of Centella asiatica extracts:
- L. Tran Van, Q. N. Vo Thi, C. Tran Van, P. T. Tran Thi, N. Pham Thi, T. Nguyen Tuan, T. H. Le Thi, N. Nguyen Thi, T. Do Thi and S. Tran Van, Synthesis of asiatic acid derivatives and their cytotoxic activity, Med. Chem. Res., 2018, 27, 1609–1623.
- T. Van Loc, V. T. Q. Nhu, T. Van Chien, L. T. T. Ha, T. T. P. Thao, T. Van Sung, Synthesis of madecassic acid derivatives and their cytotoxic activity, Zeitschrift für Naturforsch. B, 2018, 73, 91–98.
- P. T. Ninh, V. T. Q. Nhu, T. T. P. Thao, L. T. T. Ha, T. Van Loc, T. Van Chien and T. Van Sung, Chemical composition and the inhibition of acetyl cholinesterase activity of Centella asiatica from Quang Tho village, Quang Dien district, Thua Thien – Hue province, Vietnam J. Chem., 2019, 57, 347–351.
Cancer therapeutics:
- W. Fry, D. C. Bedford, P. H. Harvey, A. Fritsch, P. R. Keller, Z. Wu, E. Dobrusin, W. R. Leopold, A. Fattaey, M. D. Garrett, Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6., J. Biol. Chem., 2001, 276, 16617–23.
- U. Banerji, E. J. Dean, J. A. Pérez-Fidalgo, G. Batist, P. L. Bedard, B. You, S. N. Westin, P. Kabos, M. D. Garrett, M. Tall, H. Ambrose, J. C. Barrett, T. H. Carr, S. Y. A. Cheung, C. Corcoran, M. Cullberg, B. R. Davies, E. C. de Bruin, P. Elvin, A. Foxley, P. Lawrence, J. P. O. Lindemann, R. Maudsley, M. Pass, V. Rowlands, P. Rugman, G. Schiavon, J. Yates and J. H. M. Schellens, A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA -Mutated Breast and Gynecologic Cancers, Clin. Cancer Res., 2018, 24, 2050–2059.
- M. I. Walton, P. D. Eve, A. Hayes, A. T. Henley, M. R. Valenti, A. K. D. H. Brandon, G. Box, K. J. Boxall, M. Tall, K. Swales, T. P. Matthews, T. McHardy, M. Lainchbury, J. Osborne, J. E. Hunter, N. D. Perkins, G. W. Aherne, J. C. Reader, F. I. Raynaud, S. A. Eccles, I. Collins, M. D. Garrett, The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma, Oncotarget, 2016, 7, 2329–2342
- T. A. Yap, M. I. Walton, K. M. Grimshaw, R. H. te Poele, P. D. Eve, M. R. Valenti, A. K. de Haven Brandon, V. Martins, A. Zetterlund, S. P. Heaton, K. Heinzmann, P. S. Jones, R. E. Feltell, M. Reule, S. J. Woodhead, T. G. Davies, J. F. Lyons, F. I. Raynaud, S. A. Eccles, P. Workman, N. T. Thompson and M. D. Garrett, AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity, Clin. Cancer Res., 2012, 18, 3912–3923
Polyprodrugs:
- M. S. Akkad, C. J. Serpell, Degradable Polymers and Nanoparticles Built from Salicylic Acid, Macromol. Rapid Commun., 2018, 39, 1800182
- S. Shehata, C. J. Serpell, S. C. G. Biagini, Controlled Release of Ibuprofen from Polymeric Nanoparticles, Mater. Today Commun., 2020